JPH0155249B2 - - Google Patents
Info
- Publication number
- JPH0155249B2 JPH0155249B2 JP57003986A JP398682A JPH0155249B2 JP H0155249 B2 JPH0155249 B2 JP H0155249B2 JP 57003986 A JP57003986 A JP 57003986A JP 398682 A JP398682 A JP 398682A JP H0155249 B2 JPH0155249 B2 JP H0155249B2
- Authority
- JP
- Japan
- Prior art keywords
- fdp
- therapeutic agent
- patients
- fructose
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003814 drug Substances 0.000 claims description 7
- 230000037396 body weight Effects 0.000 claims description 5
- HBYYJIPCYANMBX-BAOOBMCLSA-M sodium;[(3s,4r,5r)-3,4,5-trihydroxy-2-oxo-6-phosphonooxyhexyl] hydrogen phosphate Chemical compound [Na+].OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)COP(O)([O-])=O HBYYJIPCYANMBX-BAOOBMCLSA-M 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000001177 diphosphate Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- 229930091371 Fructose Natural products 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- RNBGYGVWRKECFJ-ZXXMMSQZSA-N alpha-D-fructofuranose 1,6-bisphosphate Chemical compound O[C@H]1[C@H](O)[C@](O)(COP(O)(O)=O)O[C@@H]1COP(O)(O)=O RNBGYGVWRKECFJ-ZXXMMSQZSA-N 0.000 description 25
- 229940025237 fructose 1,6-diphosphate Drugs 0.000 description 22
- 238000011282 treatment Methods 0.000 description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 238000010606 normalization Methods 0.000 description 10
- 230000000144 pharmacologic effect Effects 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 5
- 159000000000 sodium salts Chemical class 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 4
- 230000035876 healing Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 208000037157 Azotemia Diseases 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000006680 metabolic alteration Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000016236 parenteral nutrition Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010004053 Bacterial toxaemia Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000032943 Fetal Distress Diseases 0.000 description 1
- 206010016855 Foetal distress syndrome Diseases 0.000 description 1
- 206010049645 Hypercatabolism Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000013222 Toxemia Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000011295 pitch Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT47554/81A IT1170618B (it) | 1981-01-13 | 1981-01-13 | Preparato farmacologico di frutto sio-1,6-difosfato ad azione terapeutica nei pazienti ustionati |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57139016A JPS57139016A (en) | 1982-08-27 |
| JPH0155249B2 true JPH0155249B2 (it) | 1989-11-22 |
Family
ID=11261053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57003986A Granted JPS57139016A (en) | 1981-01-13 | 1982-01-12 | Burn patient medicine |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JPS57139016A (it) |
| AU (1) | AU7889081A (it) |
| BE (1) | BE891316A (it) |
| DE (1) | DE3150527A1 (it) |
| FR (1) | FR2497667A1 (it) |
| GB (1) | GB2092001B (it) |
| IT (1) | IT1170618B (it) |
| LU (1) | LU83808A1 (it) |
| NL (1) | NL8105073A (it) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1156103B (it) * | 1982-07-02 | 1987-01-28 | Foscama Biomed Chim Farma | Preparato di fruttosio-1,6-difosfato ad azione antiallergica |
| IT1164363B (it) * | 1983-08-03 | 1987-04-08 | Foscama Biomed Chim Farma | Procedimento terapeutico facente uso di liposomi imcorporati fruttosio 1,6 difosfato e procedimento per la preparazione degli stessi |
| IT1204764B (it) * | 1986-01-17 | 1989-03-10 | Foscama Biomed Chim Farma | Utilizzazione terapeutica del fruttosio-1,6-difosfato per la protezione nei confronti della tossicita' indotta da somministrazione di antitumorali antraciclinici |
| US4847078A (en) * | 1987-01-14 | 1989-07-11 | Arseco, Inc. | Storage stable topical composition having moisture control agent |
| CA2016709A1 (en) * | 1989-05-15 | 1990-11-15 | University Of Cincinnati | Stable aqueous solution having high concentrations of calcium and phosphate ions and solid complex |
| GB9205800D0 (en) * | 1992-03-17 | 1992-04-29 | British Tech Group | Treatment of fibrotic disorders |
| KR100836033B1 (ko) * | 2002-05-27 | 2008-06-09 | (주)아모레퍼시픽 | 프럭토스 1,6-디포스페이트 또는 그 유도체를 함유한미백용 피부외용제 조성물 |
| ITPD20060082A1 (it) * | 2006-03-13 | 2007-09-14 | Laura Martelli | Composizione ad uso cosmetico o dermatologico |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5598198A (en) * | 1979-01-16 | 1980-07-25 | Foscama Biomed Chim Farma | Ferric salt of fructosee1*66diphosphoric acid and its manufacture |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR6065M (it) * | 1966-11-25 | 1968-05-27 | ||
| US3931402A (en) * | 1970-12-02 | 1976-01-06 | Societa Prodotti Antibiotici S.P.A. | Preparations containing hexoses |
| DE2508474A1 (de) * | 1975-02-27 | 1976-09-02 | Boehringer Mannheim Gmbh | Infusions- und spuelfluessigkeiten zur behandlung von hirnoedemen |
| IT1143956B (it) * | 1980-03-12 | 1986-10-29 | Foscama Biomed Chim Farma | Preparato di fruttosio-1,6-difosfato ad azione protettiva della membrana degli eritrociti in pazienti sottoposti a circolazione extracorporea |
-
1981
- 1981-01-13 IT IT47554/81A patent/IT1170618B/it active
- 1981-11-10 NL NL8105073A patent/NL8105073A/nl not_active Application Discontinuation
- 1981-12-01 BE BE0/206709A patent/BE891316A/fr not_active IP Right Cessation
- 1981-12-03 LU LU83808A patent/LU83808A1/fr unknown
- 1981-12-21 DE DE19813150527 patent/DE3150527A1/de not_active Withdrawn
- 1981-12-24 AU AU78890/81A patent/AU7889081A/en not_active Abandoned
- 1981-12-30 FR FR8124524A patent/FR2497667A1/fr active Pending
-
1982
- 1982-01-07 GB GB8200440A patent/GB2092001B/en not_active Expired
- 1982-01-12 JP JP57003986A patent/JPS57139016A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5598198A (en) * | 1979-01-16 | 1980-07-25 | Foscama Biomed Chim Farma | Ferric salt of fructosee1*66diphosphoric acid and its manufacture |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3150527A1 (de) | 1982-08-12 |
| BE891316A (fr) | 1982-03-31 |
| GB2092001B (en) | 1985-01-23 |
| FR2497667A1 (fr) | 1982-07-16 |
| IT1170618B (it) | 1987-06-03 |
| NL8105073A (nl) | 1982-08-02 |
| JPS57139016A (en) | 1982-08-27 |
| GB2092001A (en) | 1982-08-11 |
| AU7889081A (en) | 1982-07-22 |
| LU83808A1 (fr) | 1982-05-07 |
| IT8147554A0 (it) | 1981-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Russell et al. | Plasma nicotine levels after cigarette smoking and chewing nicotine gum. | |
| Acheson et al. | Controlled trial of dipyridamole in cerebral vascular disease | |
| Quesenberry et al. | Supportive care and emergency therapy | |
| Rocca et al. | Suramin‐induced polyneuropathy | |
| JP2012102118A (ja) | β−ヒドロキシ−β−メチル酪酸および少なくとも１つのアミノ酸を含む組成物および使用法 | |
| JP2000514091A (ja) | 心筋症の処置 | |
| Bito et al. | Transport of prostaglandins across the blood-brain and blood-aqueons barriers and the physiological significance of these absorptive transport processes | |
| Vesey et al. | Some metabolic effects of sodium nitroprusside in man | |
| WO1995003753A1 (en) | Medicinal for protection from neurological damage | |
| JPH0155249B2 (it) | ||
| Das | Insulin in sepsis and septic shock | |
| JP2009534360A (ja) | アルファ−ケトグルタレートを含む組成物およびその筋性能を調節するための使用 | |
| Cori et al. | Comparative study of the sugar concentration in arterial and venous blood during insulin action | |
| Havens Jr et al. | The production of antibody by partially hepatectomized rats | |
| Jonderko | Effect of calcitonin on gastric emptying in patients with an active duodenal ulcer. | |
| Marlow et al. | Survival for twenty-nine years in chronic lymphocytic leukemia | |
| CN109223766A (zh) | 改善人体微循环提高人体免疫力的组合物和制备工艺 | |
| BE644613A (it) | ||
| JP6153838B2 (ja) | 血管透過性抑制剤 | |
| Merritt et al. | Influence of Hyperbaric Oxygen on the Pharmacokinetics of Single‐Dose Gentamicin in Healthy Volunteers | |
| Gillon et al. | The pathology of diabetic neuropathy and the effects of aldose reductase inhibitors | |
| in't Veld et al. | Stimulated sweating in chronic renal failure. | |
| de Knegt et al. | Encephalopathy from acute liver failure and from acute hyperammonemia in the rabbit. A clinical and biochemical study | |
| Trop et al. | Role of neutrophils in the intestinal alterations associated with thermal injury | |
| Vorob’ev et al. | Colloid-chemical and medico-biological characteristics of the perfluorocarbon Ftoremulsion III |